$MCK

Smith LeAnn B sold $1.3M of MCK

Smith LeAnn B (EVP & Chief HR Officer) sold 1,810 shares of MCKESSON CORP (MCK) at $735.50 ($1.33M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Smith LeAnn B
Published Jun 2, 2026, 7:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 7:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MCK
Neutral
medium confidence
Mentioned
$MCK
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

The disclosed sale is executed under a pre-arranged Rule 10b5-1 plan, which generally lowers the probability that the trade is based on material nonpublic information.

02

Market read

Traders may monitor insider activity for sentiment, but this specific 10b5-1 sale is unlikely to drive a durable repricing.

03

What to watch

The filing doesn’t disclose reasons for the sale or any offsetting buys; net insider activity over a longer window would be more informative than a single transaction.

Relevance 6/10Novelty 6/10Timing: Filed today; sale executed on 2026-06-01

Background

The article is an SEC Form 4 insider transaction disclosure for McKesson (MCK).

Company-level read

Ticker impact

$MCKNeutralMedium confidence
Context

McKesson disclosed an EVP & Chief HR Officer open-market sale of 1,810 shares under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; any move would be more sentiment-driven than fundamental.

Evidence & confidence

The filing is an ownership-change disclosure (Form 4) with a pre-arranged 10b5-1 plan, which reduces the likelihood of information leakage.

Market effects

Minimal; this is company-specific insider activity without stated operational/regulatory catalysts.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can reflect ongoing portfolio rebalancing rather than bearish information; price reaction may be overstated.

Key entities

  • McKesson Corp

    Subject of the Form 4 insider transaction disclosure.

  • LeAnn B. Smith

    EVP & Chief HR Officer who sold shares.

Related articles

$MCKMed

McKesson Q1 Earnings Call Highlights

McKesson (NYSE: MCK) reported Q1 results supported by higher prescription and specialty volumes, partially offset by lower branded-drug pricing. GLP-1 distribution revenue rose to $15B, up about $3B (24%). Full-year guidance calls for North American Pharmaceutical revenue growth of 4% to 8%. Oncology & Multispecialty profit rose 41% to $405M. McKesson repurchased $2.5B shares and expects FY27 FCF $4.5B to $4.9B.

$MCKMedAI 8/10

Highlights of McKesson’s (MCK) Q1 2027 earnings report

McKesson (MCK) reported Q1 fiscal 2027 results. Adjusted earnings rose to $9.93 per share from $8.26 a year earlier, beating analysts. Unadjusted net income was $614 million, or $5.17 per share. Revenue increased to $105.4 billion from $97.83 billion. The company raised FY27 adjusted EPS guidance to $44.20 to $45.00.

$MCKHighAI 9/10

[MCK Q1 2027 Earnings Call] McKesson Lifts Full-Year EPS Target as North American Pharma Profit Soars 19% — BigGo Finance

McKesson reported fiscal Q1 2027 revenue of $105.4B, up 8%, and adjusted EPS of $9.93, up 20%, citing stronger North American Pharmaceutical margins. North American Pharma operating profit rose 19% to $894M on 5% revenue growth, with GLP-1 distribution revenue at $15B (+24%). McKesson raised full-year adjusted EPS guidance to $44.20–$45.00 and returned $2.6B to shareholders.